Viral core proteins are essential components of a virus's structure, playing crucial roles in the viral life cycle. These proteins are typically located at the core or nucleocapsid of the virus and are involved in packaging and protecting the viral genome. One example is the capsid protein, which forms the protective outer shell of the virus. This protein is responsible for encapsulating and shielding the viral genetic material from the host cell's defenses. The capsid may have various shapes, such as icosahedral or helical, depending on the virus type. Another critical core protein is the nucleocapsid protein, which directly interacts with the viral genome, ensuring its proper condensation and organization. The nucleocapsid protein is crucial for genome replication, transcription, and packaging. In retroviruses like HIV, the core protein, p24, forms the viral capsid, protecting the viral RNA during its journey from the host cell entry to integration into the host genome. Understanding viral core proteins is fundamental for designing antiviral strategies, as disrupting these components can inhibit viral replication and assembly. Research in this area contributes to the development of antiviral drugs and vaccines aimed at targeting the core components of various viruses.
Khursheed Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Lara Isis Teodoro
Mayo Clinic, United States
Ahmed Abdulazeez
BHRUT Trust, United Kingdom
Elena Chiappini
University of Florence, Italy
Ayesha Zahid
Griffith University, Australia
Livia Daflon Silva
Federal University of State of Rio de Janeiro, Brazil
Neha Bhandari
Chitkara University, IndiaSubmit your abstract Today
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States